Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study.

Kou MasakiMotoyasu MiyazakiHideki KakimotoYuma FukiageHaruka FukueAkio NakashimaOsamu Imakyure

Published in: Journal of clinical medicine (2023)

Our findings suggest a high probability of irAEs occurring early in ICI treatment, with a diverse range of symptoms. This underscores the need for vigilant monitoring and tailored patient management during the initial courses of ICI therapy.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
depressive symptoms
patient reported outcomes
combination therapy
drug induced